beta-thalassemia
Showing 26 - 50 of 3,307
ß-thalassemia Trial in Shenzhen (ß-globin restored autologous hematopoietic stem cells)
Recruiting
- β-thalassemia
- β-globin restored autologous hematopoietic stem cells
-
Shenzhen, Guangdong, ChinaShenzhen University General Hospital
May 8, 2023
Transfusion Dependent Beta-Thalassemia Trial in Nanning (GMCN-508B (LentiRed))
Recruiting
- Transfusion Dependent Beta-Thalassemia
- GMCN-508B (LentiRed)
-
Nanning, Guangxi, ChinaThe affiliated hospital of guangxi medical university
Feb 28, 2023
Sickle Cell Disease, Sickle Cell Trait, Beta-Thalassemia Trial (High performance liquid chromatography, Automated sickling test,
Not yet recruiting
- Sickle Cell Disease
- +4 more
- High performance liquid chromatography
- +5 more
- (no location specified)
Aug 17, 2022
Human Biospecimens for Basic and Clinical Research Into Globin
Recruiting
- Alpha and Beta Thalassemia
- +3 more
-
Bethesda, MarylandNational Institutes of Health Clinical Center
Jan 26, 2023
ß-thalassemia Trial in Shenzhen (ß-globin restored autologous hematopoietic stem cells)
Recruiting
- β-thalassemia
- β-globin restored autologous hematopoietic stem cells
-
Shenzhen, Guangdong, ChinaShenzhen Children's Hospital
Feb 24, 2023
ß-thalassemia Trial in Shanghai (BD211)
Not yet recruiting
- β-thalassemia
- BD211
-
Shanghai, ChinaShanghai Ruijin Hospital
Mar 16, 2023
Beta-Thalassemia Trial in Bulgaria, Israel, United States (VIT-2763 60 mg QD, VIT-2763 60 mg BID, VIT-2763 120 mg BID)
Withdrawn
- Beta-Thalassemia
- VIT-2763 60 mg QD
- +3 more
-
Whittier, California
- +6 more
Nov 7, 2022
Alpha-Thalassemia, Alpha Thalassemia Major, Alpha Thalassemia Minor Trial in San Francisco
Recruiting
- Alpha-Thalassemia
- +2 more
-
San Francisco, CaliforniaUniversity of California San Francisco
Oct 7, 2022
Sickle Cell Disease, Hb-SS Disease, Hemoglobin S Trial run by the National Heart, Lung, and Blood Institute (NHLBI)
Not yet recruiting
- Sickle Cell Disease
- +5 more
-
Bethesda, MarylandNational Institutes of Health Clinical Center
Jun 21, 2023
Beta Thalassemia Major, Beta Thalassemia Intermedia Trial in Worldwide (SOTATERCEPT (ACE-011))
Completed
- Beta Thalassemia Major
- Beta Thalassemia Intermedia
- SOTATERCEPT (ACE-011)
-
Créteil, France
- +14 more
Aug 18, 2022
Beta-Thalassemia, Thalassemia, Genetic Diseases, Inborn Trial in Nashville (CTX001)
Recruiting
- Beta-Thalassemia
- +4 more
- CTX001
-
Nashville, Tennessee
- +5 more
Feb 2, 2023
Transfusion Dependent Beta-thalassemia Trial in United States (ST-400 Investigational product)
Active, not recruiting
- Transfusion Dependent Beta-thalassemia
- ST-400 Investigational product
-
Los Angeles, California
- +5 more
Jul 6, 2022
Pulmonary Functions and Physical Fitness in ß-thalassemia
Recruiting
- β-Thalassemia
- +2 more
- no intervention
-
Cairo, EgyptEsraa Elsayed
Aug 8, 2022
QoL of Pediatric Patients After HSCT and Its Influencing Factors
Not yet recruiting
- Thalassemia Major
- Acute Leukemia
- Conventional nursing
-
Guangzhou, Guangdong, ChinaSun Yat-sen Memorial Hospital, Sun Yat-sen University
Sep 4, 2023
Transfusion Dependent Beta-Thalassaemia Trial in Nanning (ET-01)
Recruiting
- Transfusion Dependent Beta-Thalassaemia
- ET-01
-
Nanning, Guangxi, ChinaPLA 923 Hospital
Mar 2, 2023
Beta-Thalassemia, Thalassemia, Hematologic Diseases Trial (CTX001)
Not yet recruiting
- Beta-Thalassemia
- +6 more
- CTX001
- (no location specified)
Jul 26, 2022
Minimisation Measures for REBLOZYL Among Healthcare
Active, not recruiting
- Myelodysplastic Syndromes
- Beta-thalassemia
-
City, State, AustriaLocal Institution
Aug 4, 2022
The Prevelence of IVS 1-6 [HBB:c.92 +6 T-C] Gene Mutation in
Not yet recruiting
- Beta-Thalassemia
- ARMS
- (no location specified)
May 10, 2022
ß Thalassemia Major Trial in Shanghai (?-globin reactivated autologous hematopoietic stem cells)
Active, not recruiting
- β Thalassemia Major
- γ-globin reactivated autologous hematopoietic stem cells
-
Shanghai, Shanghai, ChinaShanghai Bioray Laboratories Inc.
Oct 9, 2022
Alpha Thalassemia Major, Hemoglobinopathy; With Thalassemia, Hemoglobinopathies Trial in San Francisco (in utero hematopoietic
Enrolling by invitation
- Alpha Thalassemia Major
- +8 more
- in utero hematopoietic stem cell transplantation
-
San Francisco, CaliforniaUniversity of California
Oct 28, 2022
Beta-Thalassemia, Thalassemia, Genetic Diseases, Inborn Trial in Worldwide (CTX001)
Active, not recruiting
- Beta-Thalassemia
- +4 more
- CTX001
-
Stanford, California
- +11 more
Nov 30, 2022
Thalassemia Major, Transfusion-dependent Anemia Trial in Guangzhou (Luspatercept Injectable Product)
Recruiting
- Thalassemia Major
- Transfusion-dependent Anemia
- Luspatercept Injectable Product
-
Guangzhou, Guangdong, ChinaThe second affiliated hospital of Sun Yat-sen University
Jul 15, 2022